Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study of glycopyrronium or indacaterol + glycopyrronium in moderate COPD
2013-003127-11Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of glycopyrronium and indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Superiority of glycopyrronium versus short-acting bronchodilators on FEV1 at week 12. Started Jan 2014; status: completed.
02
Drugs
glycopyrroniumindacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-003127-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003127-11.